Neue Aspekte der MS-Therapie mit Glatiramerazetat - eine aktuelle Übersicht

Zusammenfassung

Ein Zuwachs an Evidenzbasis kennzeichnet die aktuelle Datenlage zur Anwendung von Glatiramerazetat (auch als Copolymer-1, „Copaxone®” bekannt) in der Therapie der multiplen Sklerose (MS). Neue In-vitro-Ergebnisse deuten auf anti-inflammatorische Zytokinmusterveränderungen und eine Verschiebung der zellulären Immunantwort in Richtung eines TH2-Überwiegens. Magnetresonanztomographische Ergebnisse einer jüngst abgeschlossenen multizentrischen Studie an 239 Patienten mit schubförmiger MS zeigten über einen Zeitraum von neun Monaten gegenüber Plazebo eine signifikante Reduktion kontrastmittelaktiver Läsionen um 29 % sowie eine Reduktion der Zunahme des zerebralen T2-Läsionsvolumens um 45 %. Damit liegen auch für Glatiramerazetat vergleichbare quantitative Wirkungsbelege wie für andere moderne Immuntherapeutika bei MS vor. Vielversprechend für die zukünftige therapeutische Anwendung sind Beobachtungen über Wirksamkeit oraler Gaben der Zubereitung in Tiermodellen.

New Aspects of MS Therapy with Glatiramer Acetate - An Update Review

A growing body of evidence characterizes the status of glatiramer acetate (formerly named Copolymer-1) in MS therapy. Recent in-vitro findings indicate induction of anti-inflammatory cytokine shifts and a TH2-weighted cellular immune response. Magnetic resonance imaging findings from a recent multicenter study in 239 patients with remitting-relapsing multiple sclerosis demonstrate a 29 % reduction in contrast-enhancing lesions compared to placebo over a 9-month period. Increase of cerebral T2-lesion load was reduced by 45 %. Observations of effective oral administrations in animal models are promising for future therapeutic strategies in man.

Literatur

• 1  MS-Therapie Konsensus Gruppe (MSTKG). Immunmodulatorische Stufentherapie der multiplen Sklerose.  Nervenarzt. 1999;  70 371-386
• 2 Van der Noort S, Eidelman B, Rammohan K. et al .National Multiple Sclerosis Society NMSS: Disease Management Consensus Statement. New York; National MS Society 1998
• 3 Dang T, Goebels N, Walther E U, Hohlfeld R. Copolymer-1 (Glatirameracetat) zur Therapie der schubförmigen multiplen Sklerose.  Akt Neurol. 1998;  25 159-164
• 4 Teitelbaum D, Meshorer T, Hirshfeld T. et al . Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.  Eur J Immunol. 1971;  1 242-248
• 5 Lobel E, Riven-Kreitman R, Amsalem A. et al . Copolymer-1.  Drugs Future. 1996;  21 131-134
• 6 Teitelbaum D, Arnon R, Sela M. Immunomodulation of experimental allergic encephalomyelitis by oral administration of copolymer 1.  Proc Natl Acad Sci USA. 1999;  96 3842-3847
• 7 Weiner H L. Oral tolerance with Copolymer 1 for the treatment of multiple sclerosis.  Proc Natl Acad Sci USA. 1999;  96 3333-3335
• 8 Hemmer B, Martin R. Neuroimmunologie und multiple Sklerose.  Akt Neurol. 1998;  25 83-95
• 9 Aharoni R, Teitelbaum D, Sela M. et al . Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.  Proc Natl Acad Sci USA. 1997;  94 10 821-10 826
• 10 Miller A, Shapiro S, Gershtein R. et al . Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune deviation.  J Neuroimmunol. 1998;  92 113-121
• 11 Duda P W, Schmied M C, Cokk S L. et al . Glatiramer acetate (COPAXONE®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.  J Clin Invest. 2000;  105 967-976
• 12 Neuhaus O, Farina C, Yassouridis A. et al . Multiple Sklerosis: Comparison of copolimer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.  Proc Natl Ac Sci. 2000;  97 7452-7457
• 13 Bernard C A, Leydon J, Mackay I R. T-cell necessitiy in the pathogenesis of experimental autoimmune encephalomyelitis in mice.  Eur J Immunol. 1976;  6 655-660
• 14 Fridkis Hareli M, Teitelbaum D, Gurevich M. et al . Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen presenting cells - specifity and promiscuity.  Proc Natl Acad Sci USA. 1994;  91 4872-4876
• 15 Ben Nun A, Mendel I, Bakimer R. et al . The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease.  J Neurol. 1996;  243 14-22
• 16 Teitelbaum D, Fridkis Hareli R, Arnon R. et al . Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T-cell responses.  J Neuroimmunol. 1996;  64 209-217
• 17 Arnon R, Sela M, Teitelbaum D. New insights into the mechanisms of action of copolymer 1 in experimental autoimmune encephalomyelitis and multiple sclerosis.  J Neurol. 1996;  243 8-13
• 18 Abramsky O, Teitelbaum D, Arnon R. Effect of a synthetic polypeptide (COP) on patients with multiple sclerosis and with acute disseminated encephalomyelitis.  J Neurol Sci. 1977;  31 433-438
• 19 Bornstein M B, Miller A, Slagle S. et al . A pilot trial of COP1 in exacerbating-remitting multiple sclerosis.  N Engl J Med. 1987;  317 408-414
• 20 Johnson K P, Brooks B R, Cohen J A. et al . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.  Neurology. 1995;  45 1268-1276
• 21 Johnson K P, Brooks B R, Cohen J A. et al . Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability.  Neurology. 1998;  50 701-708
• 22 Hofstadt U, Leclaire J, Raguz J M. et al . Delayed-type hypersensitivity to glatiramer acetate (Copaxone®): report of three cases.  J Neurol. 1999;  245 418
• 23 Teitelbaum D, Brenner T, Sela M. et al . Antibodies in copolymer I do not interfer with its therapeutic effect.  Eur J Neurol. 1996;  3 314
• 24 Cohen J A, Grossmann R I, Udupa J K. et al . Assessment of the efficiacy of copolymer 1 in the treatment of multiple sclerosis by quantitative MRI.  Neurology. 1995;  45, Suppl 4 A418
• 25 Mancardi G L, Sardanelli F, Parodi R C. et al . Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis.  Neurology. 1998;  50 1127-1133
• 26 Ge Y, Grossmann R I, Udupa J K. et al . Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS.  Neurology. 2000;  54 813-817
• 27 Thompson A J, Kermode A G, Wick D. Major differences in the dynamics of primary and secondary multiple sclerosis.  Ann Neurol. 1991;  29 53-62
• 28 O'Riordan J I, Thompson A J, Kingsley D PE. et al . The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.  Brain. 1998;  121 495-503
• 29 Filippi M, Paty D W, Kappos L. et al . Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study.  Neurology. 1995;  45 255-260
• 30 Khoury S J, Guttmann C R, Orav E J. et al . Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden.  Neurology. 1994;  44 2120-2124
• 31 Kidd D, Thompson A J, Kendall B E. et al . Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity.  J Neurol Neurosurg Psych. 1994;  57 1070-1072
• 32 Kappos L, Moeri D, Schweikert K. et al . Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta analysis.  Lancet. 1999;  353 664-666
• 33 Kesselring J, Miller D H, MacManus D G. et al . Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone.  J Neurol Neurosurg Psych. 1989;  52 14-17
• 34 Kermode A G, Thompson A J, Moseley I F. et al . Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications.  Brain. 1990;  113 1477-1489
• 35 Paty D W, Li D KB,  the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis.  Neurology. 1993;  43 662-667
• 36 Stone L, Frank J A, Albert P S. et al . Characterization of MRI response to treatment with interferon beta-1b.  Contrast-enhancing MRI lesion frequency as a primary outcome measure.. Neurology. 1997;  49 862-968
• 37 Miller D H. Magnetic resonance in monitoring the treatment of multiple sclerosis.  Ann Neurol. 1994;  36, Suppl 92-94
• 38 Van Walderveen M A, Barkhof F, Hommes O R. et al . Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-(T1-weighted) spin-echo images.  Neurology. 1995;  45 1684-1690
• 39 Jacobs L D, Cookfair D L, Rudick R A. et al . Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.  Ann Neurol. 1996;  39 285-294
• 40  PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.  Lancet. 1998;  352 1498-1504
• 41 Krapf H, Morrissey S P, Zenker O. et al . Mitoxantrone in progressive multiple sclerosis: MRI results of the european phase III trial.  Neurology. 1999;  Suppl 2 A495
• 42 Noseworthy J H, Gold R, Hartung H P. Treatment of multiple sclerosis: recentrials and future perspectives.  Current Opinion in Neurology. 1999;  12 279-293
• 43 Comi G, Filippi M,  and the Copaxone MRI Study Group. The effect of glatiramer acetate (Copaxone®) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment.  Neurology. 1999;  52, Suppl 2 A289
• 44 Milo R, Panitch H. Additive effects of copolymer 1 and interferon beta 1b on the immune response to MBP.  J Neuroimmunol. 1995;  61 185-193